Case Study: Distinguishing Catatonia-like Symptoms from Catatonia in a Schizophrenia Patient with Guillain–Barré Syndrome - Scorecard - MDSpire

Case Study: Distinguishing Catatonia-like Symptoms from Catatonia in a Schizophrenia Patient with Guillain–Barré Syndrome

  • By

  • Lishan Ren

  • Wenjuan Liu

  • Hongjing Mao

  • Kaiyuan Zhang

  • April 21, 2026

  • 0 min

Share

Clinical Scorecard: Case Study: Distinguishing Catatonia-like Symptoms from Catatonia in a Schizophrenia Patient with Guillain–Barré Syndrome

At a Glance

CategoryDetail
Condition
Key MechanismsPsychotic symptoms and motor impairment due to neurological involvement, emphasizing the diagnostic challenge.
Target Population
Care Setting

Key Highlights

  • Catatonia can mimic neurological disorders like Guillain–Barré Syndrome.
  • Thorough neurological assessment is crucial in patients with acute mutism and immobility.
  • Misdiagnosis can lead to inappropriate psychiatric interventions.
  • Comprehensive history taking is essential, especially post-infection.
  • Risperidone was effective for managing schizophrenia symptoms.
  • Consider lumbar puncture for diagnosis of comorbid neurological disorders.

Guideline-Based Recommendations

Diagnosis

  • Utilize DSM-5 criteria for schizophrenia diagnosis.
  • Consider differential diagnosis for catatonia-like symptoms.
  • Incorporate neurological assessment techniques in diagnosis.

Management

  • Initiate antipsychotic treatment for schizophrenia.
  • Administer intravenous immunoglobulin for Guillain–Barré Syndrome.

Monitoring & Follow-up

  • Regular follow-up to assess psychiatric and neurological symptoms.

Risks

  • Risk of misdiagnosis leading to delayed treatment of underlying conditions.

Patient & Prescribing Data

Risperidone 4 mg as maintenance therapy post-recovery, initiated after GBS treatment.

Clinical Best Practices

  • Prioritize neurological evaluation in patients with psychiatric symptoms.
  • Be vigilant for signs of comorbid medical conditions in psychiatric patients.
  • Encourage adherence to medication to prevent relapses.
  • Foster interdisciplinary collaboration for comprehensive patient management.

References

Original Source(s)

Related Content